Search - tctmd.com

Displaying 1 - 20 of 48

Sort: Relevancy | Date

Presentation AHA 2024

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

Presenter: Chisato Izumi

November 17, 2024

Presentation EuroPCR 2024

Impact of valve type and anaesthesia strategy for TAVI – 5-year results of the SOLVE-TAVI trial

Presenter: Hans-Josef Feistritzer

May 14, 2024

Presentation Miami Valves 2022

Do We Understand Neuroprotection Better?

Presenter: Carlos Alfonso

February 03, 2022

Presentation Live Valves 2019

TAVI: Cerebral Protection for Everyone

Presenter: Susheel Kodali

December 10, 2019

Presentation TCT Abstracts Posters 2019

Incidence, predictors and outcomes of periprocedural stroke in patients undergoing TAVR: Report from National Inpatient sample

Presenter: Moinuddin Syed

October 28, 2019

Presentation SIF 2019

Unresolved Issues: Cerebral Embolic Protection Use Selectively!

Presenter: Steven J Yakubov

March 30, 2019

Presentation JIM 2019

Optimizing your TAVI program with Cerebral embolic protection: a case based approach

Presenter: Francesco Bedogni

February 14, 2019

Presentation EuroPCR 2018

Anatomical Predictors of Stroke Prevention During Transcatheter Aortic Valve Implantation: The SENTINEL Trial

Presenter: Hasan Jilaihawi

May 23, 2018

Presentation SCAI 2018

Unresolved Issues: Cerebral Embolic Protection Use Selectively!

Presenter: Steven J Yakubov

April 28, 2018

Presentation JIM 2018

Prime Time For..."Protected TAVI"

Presenter: Martin B. Leon

February 23, 2018

Presentation Cardiovascular Interventions 2017

How Me The Data: Key Clinical Trials of 2017

Presenter: Curtiss T. Stinis

November 09, 2017

Presentation

TAVR is Here and Mainstream: With the Risk of Stroke During Any Valvular Procedure: Is There Any Role for Embolic Protection?

Presenter: John D. Carroll,

October 06, 2017

Presentation CDM 2017

TAVR is Here and Mainstream: With the Risk of Stroke During Any Valvular Procedure: Is There Any Role for Embolic Protection?

Presenter: John D. Carroll

October 06, 2017

Presentation LAA 2017

Left Atrial Appendage Occlusion as Adjunctive Therapy

Presenter: Amar Krishnaswamy

July 21, 2017

Presentation JIM 2017

Complete Cerebral Embolic Protection Utilizing TriGuard™

Presenter: Azeem Latib

February 10, 2017

Presentation Cardiovascular Interventions 2016

Unprotected Left Main Stenting

Presenter: Paul S. Teirstein

November 10, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: RESPECT Final Long-term Outcomes

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Michael J. Mullen

November 01, 2016

Presentation

Timing, Risk Factors, Outcomes of Stroke, TIA after TAVR: PARTNER Trial

Presenter: Samir Kapadia

September 12, 2016

Presentation

Neurological Events Following TAVR and Their Predictors: CoreValve Trials

Presenter: Neal Kleiman

September 12, 2016

Presentation TVT 2016

Strokes After TAVR: Etiologies, Declining Frequency, and Current and Future Therapies

Presenter: Samir R. Kapadia

June 17, 2016

Advertisement

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

Impact of valve type and anaesthesia strategy for TAVI – 5-year results of the SOLVE-TAVI trial

Do We Understand Neuroprotection Better?

TAVI: Cerebral Protection for Everyone

Incidence, predictors and outcomes of periprocedural stroke in patients undergoing TAVR: Report from National Inpatient sample

Unresolved Issues: Cerebral Embolic Protection Use Selectively!

Optimizing your TAVI program with Cerebral embolic protection: a case based approach

Anatomical Predictors of Stroke Prevention During Transcatheter Aortic Valve Implantation: The SENTINEL Trial

Unresolved Issues: Cerebral Embolic Protection Use Selectively!

Prime Time For..."Protected TAVI"

How Me The Data: Key Clinical Trials of 2017

TAVR is Here and Mainstream: With the Risk of Stroke During Any Valvular Procedure: Is There Any Role for Embolic Protection?

TAVR is Here and Mainstream: With the Risk of Stroke During Any Valvular Procedure: Is There Any Role for Embolic Protection?

Left Atrial Appendage Occlusion as Adjunctive Therapy

Complete Cerebral Embolic Protection Utilizing TriGuard™

Unprotected Left Main Stenting

Highlights (and my Interpretations) From: RESPECT Final Long-term Outcomes

Timing, Risk Factors, Outcomes of Stroke, TIA after TAVR: PARTNER Trial

Neurological Events Following TAVR and Their Predictors: CoreValve Trials

Strokes After TAVR: Etiologies, Declining Frequency, and Current and Future Therapies

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content